Most countries in the European Union (EU) recommend and fund seasonal influenza vaccine for elderly people and individuals at increased risk of severe influenza \[[@r1]\]. The United Kingdom (UK) commenced the incremental introduction of a universal childhood influenza vaccination programme in 2013/14 using a quadrivalent live attenuated influenza vaccine (LAIV4) for healthy children and quadrivalent inactivated vaccine (QIV) for at-risk children for whom LAIV4 is contraindicated \[[@r2]\].

The trivalent influenza vaccines for the 2017/18 northern hemisphere influenza season include an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like virus (B/Victoria lineage). The quadrivalent vaccines also contain a B/Phuket/3073/2013-like virus (B/Yamagata lineage) \[[@r3]\].

The early phase of the 2017/18 influenza season in Europe was characterised by the co-circulation of influenza A(H1N1)pdm09, influenza A(H3N2) and influenza B, with different patterns of dominant type or subtype observed between countries \[[@r4]\]. Up to February 2018, most influenza B viruses assigned to a lineage were B/Yamagata viruses, not included in the 2017/18 trivalent vaccine \[[@r3],[@r4]\].

Here we present the interim 2017/18 season influenza vaccine effectiveness (VE) estimates from three single-country studies (UK, Denmark (DK) and Spain (ES)) and two multi-country studies (primary care (EU-PC) and hospital (EU-H) European Influenza - Monitoring Vaccine Effectiveness (I-MOVE/I-MOVE+) networks) ([Figure 1](#f1){ref-type="fig"}).
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Study design and estimation of vaccine effectiveness
====================================================

The methods of these five studies have been described in detail elsewhere \[[@r5]-[@r9]\]. Study sites included in EU-PC (Croatia, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain and Sweden) and EU-H (France, Italy, the Netherlands, Portugal and Spain) followed generic protocols for primary care-based or hospital-based studies.

All five studies used a test-negative case control design (TND) \[[@r10]\]. In short, individuals presenting at participating healthcare settings with a pre-determined set of symptoms (including at least one systemic and one respiratory symptom) were swabbed. Samples were tested for influenza using RT-PCR. Individuals testing positive for influenza were classified as cases (by influenza (sub)type), those testing negative as controls.

The ES, UK and EU-PC studies included patients at primary care level (henceforth referred to as medically attended), the EU-H study included patients at hospital level (henceforth referred to as hospitalised), and the DK study included results from primary care and hospital level pooled together. Patients' inclusion was foreseen to be systematic (or exhaustive) in the ES, EU-PC and EU-H studies and ad hoc in the DK and UK studies. In Spain, 268 of the 833 physicians included in the ES study were also included in the EU-PC study.

The study population included all age groups in all studies except for EU-H, which was confined to individuals 65 years and older.

In all studies, we defined patients as vaccinated with the 2017/18 influenza vaccine if they had been vaccinated at least 14 days (UK) or 15 days (all other studies) before symptom onset. Patients were excluded if they were vaccinated less than 14 (UK) or 15 days (all other studies) before symptom onset or if the date of vaccination was unknown.

In seven EU-PC countries (France, Germany, Ireland, the Netherlands, Portugal, Spain and Sweden), the UK, ES and DK, all or a random sample of positive influenza specimens were selected for genetic sequencing.

VE was computed by comparing the odds of vaccination between cases and controls (VE = (1 − OR) × 100). All studies used logistic regression to adjust VE for measured confounding variables, excluding patients with missing data for covariates in the model (complete case analysis) ([Table 1](#t1){ref-type="table"}). We computed VE overall and, where possible, by age group and target population (as defined locally in the various studies and study sites) against any influenza, influenza A(H3N2), influenza A(H1N1)pdm09, any influenza B and influenza B/Yamagata.

###### Summary characteristics of the influenza vaccine effectiveness studies included, Europe, influenza season 2017/18 (n = 21,220)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   ES                                                                  UK                                                                                            EU-PC                                                                                       DK                                                                                                                        EU-H
  ------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study period                    30 Oct 2017 to 21 Jan 2018                                           1 Oct 2017 to 14 Jan 2018                                                                     25 Sep 2017 to 26 Jan 2018                                                                  1 Dec 2017 to 5 Feb 2018                                                                                                  25 Oct 2017 to 4 Feb 2018

  Setting                         Primary care                                                         Primary care                                                                                  Primary care                                                                                Primary care and hospital                                                                                                 Hospital

  Location                        Spain                                                                England, Scotland, Northern Ireland and Wales                                                 Croatia, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain and Sweden       Denmark                                                                                                                   France, Italy, the Netherlands, Portugal and Spain

  Study design                    TND                                                                  TND                                                                                           TND                                                                                         TND                                                                                                                       TND

  Data source                     Sentinel physicians and laboratory                                   Sentinel physicians and laboratory                                                            Sentinel physicians and laboratory^a^                                                       Data linkage of Danish Microbiology Database, the Danish Vaccination Register and the Danish National Hospital Register   Hospital charts, vaccine registers, interviews with GPs/pharmacists, laboratory

  Age group of study population   All                                                                  All                                                                                           ≥ 6 months                                                                                  ≥ 18 years                                                                                                                ≥ 65 years

  Case definition                 ILI                                                                  ILI                                                                                           ILI                                                                                         ILI                                                                                                                       SARI

  Selection of patients           Systematic                                                           At practitioner\'s discretion                                                                 Systematic                                                                                  At practitioner\'s discretion                                                                                             Exhaustive

  Vaccine types used^b^           Mostly TIV (no individual data)                                      In children: 19% TIV, 77% LAIV4 nasal spray, 3% unknown\                                      67% TIV, 17% unknown, 8% TIV adjuvanted, 4% QIV, 3% TIV intradermal, 1% LAIV4 nasal spray   Only TIV (no individual data)                                                                                             57% TIV, 25% unknown, 8% TIV adjuvanted, 10% TIV intradermal
                                                                                                       In adults: 100% unknown                                                                                                                                                                                                                                                                                             

  Variables of adjustment         Age (RCS), sex, presence of chronic conditions, onset date, region   Age group, sex, onset date, pilot area for child vaccination programme, surveillance scheme   Age (RCS), sex, presence of chronic conditions, onset date and study site                   Age group, sex, presence of chronic conditions, onset date                                                                Age (RCS), lung diseases, heart diseases, diabetes mellitus, obesity (BMI ≥ 30), renal diseases, cancer and hospitalisation in the past 12 months, onset date, study site
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DK: Denmark study; ES: Spain study; EU-H: European hospital-based multi-country I-MOVE+ study; EU-PC: European primary care-based multi-country I-MOVE/I-MOVE+ study; GP: general practitioner; ILI: influenza-like illness; LAIV4: quadrivalent live attenuated influenza vaccines; LRI: lower respiratory infection; SARI: severe acute respiratory infection; TIV: trivalent inactivated vaccines; TND: test-negative design; RCS: restricted cubic spline; UK: United Kingdom study.

^a^ In Spain, 268 of the 833 physicians included in the ES study were also included in the EU-PC study.

^b^ Vaccines were egg-propagated, non-adjuvanted and administered intramuscularly unless otherwise specified.

If the number of events per parameter was lower than 10, we conducted a sensitivity analysis using penalised logistic regression to assess small sample bias \[[@r11]\].

Results
=======

Between September 2017 and February 2018, the number of patients included in the VE analysis by study was 2,399 (1,452 cases) in the ES, 1,331 (421 cases) in the UK, 4,652 (2,103 cases) in the EU-PC, 11,907 (3,011 cases) in the DK and 931 (385 cases) in the EU-H study. Overall, more than two thirds of cases were positive for influenza B viruses in all studies except UK, where influenza A and B viruses were detected in similar proportions (51% (214/423) and 49% (209/423), respectively) ([Figure 2](#f2){ref-type="fig"}). Where subtyped, influenza A viruses were mainly A(H3N2) in ES (62% (233/375) of subtyped influenza A specimens), UK (90% (174/194)) and EU-H (74% (68/92)), and mainly A(H1N1)pdm09 in DK (56% (145/257)) and EU-PC (67% (469/698)).

![Proportion of influenza (sub)types by study, Europe, 2017/18 (n = 6,979)](18-00086-f2){#f2}

Any influenza
-------------

Among all ages, VE against any medically attended influenza ranged between 25% (95% confidence interval (CI): −10 to 48) in the UK study and 52% (95% CI: 29 to 67) in the ES study. In UK, VE of the LAIV4 was 53% (95% CI: −56 to 86) in children and VE of the inactivated vaccine was 18% (95% CI: −23 to 45) in adults ([Table 2](#t2){ref-type="table"}). Among the target groups for influenza vaccination, the VE was 36% (95% CI: 13 to 53) in EU-PC and 40% (95% CI: 1 to 63) in the ES study. In EU-H, VE against any hospitalised influenza in patients aged 65 years and older was 35% (95% CI: 13 to 51).

###### Interim adjusted seasonal vaccine effectiveness against any laboratory-confirmed influenza, influenza A(H1N1)pdm09, A(H3N2) and B, by age group, target group for vaccination and by study, Europe, influenza season 2017/18

  Influenza type/subtype and study site   Setting           Study population   Cases   Controls   Adjusted VE   95% CI                              
  --------------------------------------- ----------------- ------------------ ------- ---------- ------------- -------- ------- ------------ ----- ------------
  **Influenza A + B**                                                                                                                               
  ES                                      PC                All ages           1,452   98         7             947      75      8            52    29 to 67
  0--14 years                             589               15                 3       370        13            4        78      45 to 91           
  15--64 years                            762               44                 6       511        40            8        54      23 to 73           
  ≥ 65 years                              101               42                 42      66         22            33       21      −93 to 68          
  Target group^a^                         278               72                 26      180        50            28       40      1 to 63            
  UK                                      PC                All ages           421     93         22            910      190     21           25    −10 to 48
  2--17 years (LAIV4)                     69                5                  7       166        19            11       53      −56 to 86          
  ≥ 18 years (IIV)                        347               87                 25      630        163           26       18      −23 to 45          
  EU-PC                                   PC                All ages           2,103   210        10            2,549    272     11           38    20 to 52
  0--17 years                             846               26                 3       998        35            4        59      23 to 78           
  18--64 years                            1,021             74                 7       1,288      109           8        34      5 to 54            
  ≥ 65 years                              234               110                47      262        128           49       44      8 to 66            
  Target group^a^                         554               172                31      713        217           30       36      13 to 53           
  DK                                      PC and hospital   All ages           3,011   593        20            8,896    2299    26           34    25 to 41
  18--64 years                            1,564             136                9       3,462      538           16       47      35 to 58           
  ≥ 65 years                              934               447                48      3,089      1,688         55       23      10 to 34           
  EU-H                                    Hospital          ≥ 65 years         385     200        52            546      332     61           35    13 to 51
  **Influenza A(H1N1)pdm09**                                                                                                                        
  EU-PC                                   PC                All ages           444     14         3             1,999    195     10           68    42 to 83
  18--64 years                            203               7                  3       955        77            8        63      12 to 84           
  DK                                      PC and hospital   All ages           214     18         8             8,896    2299    26           55    23 to 74
  18--64 years                            119               7                  6       3,462      538           16       60      13 to 82           
  ≥ 65 years                              26                11                 42      3,089      1,688         55       37      −40 to 72          
  **Influenza A(H3N2)**                                                                                                                             
  ES                                      PC                All ages           233     22         9             947      75      8            7     −74 to 51
  UK                                      PC                All ages           194     58         30            910      190     21           −27   −111 to 24
  EU-PC                                   PC                All ages           220     35         16            1,505    147     10           −16   −96 to 31
  18--64 years                            140               9                  6       771        66            9        27      −62 to 67          
  DK                                      PC and hospital   All ages           122     53         43            8,896    2,299   26           -42   −116 to 7
  18--64 years                            45                6                  13      3,462      538           16       21      −95 to 68          
  ≥ 65 years                              67                45                 67      3,089      1,688         55       −65     −178 to 2          
  EU-H                                    Hospital          ≥ 65 years         60      38         63            242      154     64           −1    −93 to 47
  **Any influenza B**                                                                                                                               
  ES                                      PC                All ages           1,022   72         7             947      75      8            52    27 to 68
  0--17 years                             440               10                 2       370        13            4        83      54 to 94           
  18--64 years                            503               31                 6       511        40            8        51      13 to 72           
  ≥ 65 years                              79                31                 39      66         22            33       15      −114 to 66         
  Target group^a^                         207               53                 26      180        50            28       38      −5 to 63           
  UK                                      PC                All ages           209     33         16            910      190     21           54    24 to 72
  EU-PC                                   PC                All ages           1,368   150        11            2,510    269     11           39    19 to 54
  0--17 years                             562               21                 4       980        35            4        58      15 to 79           
  18--64 years                            643               55                 9       1,279      108           8        27      −9 to 51           
  ≥ 65 years                              161               74                 46      250        126           50       54      20 to 73           
  Target group^a^                         382               125                33      696        215           31       39      14 to 56           
  DK                                      PC and hospital   All ages           2,298   437        19            8,896    2,299   26           36    27 to 44
  18--64 years                            1,220             111                9       3,462      538           16       44      30 to 56           
  ≥ 65 years                              701               319                46      3,089      1,688         55       28      14 to 39           
  EU-H                                    Hospital          ≥ 65 years         249     131        53            524      321     61           34    8 to 52
  **Influenza B/Yamagata**                                                                                                                          
  ES                                      PC                All ages           84      4          5             993      81      8            77    14 to 94
  EU-PC^b^                                PC                All ages           395     34         9             2,065    206     10           49    19 to 67

CI: confidence interval; DK: Denmark study; ES: Spain study; EU-H: European hospital-based multi-country I-MOVE+ study; EU-PC: European primary care-based multi-country I-MOVE/I-MOVE+ study; PC: primary care; UK: United Kingdom study; Vacc: vaccinated; VE: vaccine effectiveness.

^a^ Groups targeted by seasonal influenza vaccination as defined locally in the studies and study sites.

^b^ Only includes study sites where lineage was available for all samples or where lineage was determined systematically.

Study sites included in the EU-H analysis: France, Italy, Navarra, the Netherlands, Portugal and Spain (except for influenza A(H3N2) analysis: Navarra and Spain only).

Study sites included in EU-PC analysis for all influenza and influenza B: Croatia, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden. For analysis against A(H1N1)pdm09: France, Germany, Italy and Spain were included. For analysis against A(H3N2): France, Germany, Ireland, Spain and Sweden were included.

Influenza A(H1N1)pdm09
----------------------

All 76 influenza A(H1N1)pdm09 viruses sequenced belonged to clade 6B.1 (A/Michigan/45/2015) ([Table 2](#t2){ref-type="table"}).

VE against influenza A(H1N1)pdm09 was 68% (95% CI: 42 to 83) and 55% (95% CI: 23 to 74) among all ages in the EU-PC and DK studies, respectively. Among 18--64 year-olds, it was 63% (95% CI: 12 to 84) and 60% (95% CI: 13 to 82) in the EU-PC and DK studies, respectively. Among those aged 65 years and older, it was 37% (95% CI: −40 to 72) in the DK study ([Table 2](#t2){ref-type="table"}).

Influenza A(H3N2)
-----------------

Of the 204 influenza A(H3N2) viruses sequenced, 63% (n = 129) belonged to genetic clade 3C.2a, 35% (n = 72) to 3C.2a1 and 1% (n = 3) to 3C.3a ([Table 3](#t3){ref-type="table"}).

###### Influenza viruses characterised by clade and study site, Europe, influenza season 2017/18 (n = 886)

                                         Clade               ES ^a^   UK          EU-PC^b^   DK^c^                                  
  -------------------------------------- ------------------ --------- ----------- ---------- --------- -------- --------- --------- ---------
  Total influenza A(H1N1)                n = 142            n = 20    n = 469     n = 113                                           
  Sequenced                              28                 100       10          100        25        100      23        100       
  **A/Michigan/45/2015**                 **6B.1**           **28**    **100**     **10**     **100**   **25**   **100**   **23**    **100**
  Total influenza A(H3N2)                n = 233            n = 174   n = 229     n = 144                                           
  Sequenced                              51                 100       59          100        43        100      51        100       
  **A/HongKong/4801/2014**               **3C.2a**          **20**    **39**      **46**     **78**    **27**   **63**    **36**    **71**
  **A/Singapore/INFIMH-16--0019/2016**   **3C.2a1**         **31**    **61**      **10**     **17**    **16**   **37**    **15**    **29**
  **A/Switzerland/9715293/2013**         **3C.3a**          **0**     **0**       **3**      **5**     **0**    **0**     **0**     **0**
  Total influenza B                      n = 1,022          n = 209   n = 1,469   n = 625                                           
  Sequenced                              164                100       116         100        207       100      109       100       
  **B/Yamagata**                         **136**            **83**    **116**     **100**    **198**   **96**   **109**   **100**   
  B/Phuket/3073/2013                     3                  136       100         0          0         198      100       109       100
  **B/Victoria**                         **28**             **17**    **0**       **0**      **9**     **4**    **0**     **0**     
  B/Norway/2409/2017                     1A Δ(K162, N163)   20        71          0          0         5        56        0         0
  B/Brisbane/60/2008                     1A                 8         29          0          0         4        44        0         0

^a^ 50 specimens from ES are also included in EU-PC data.

^b^ The specimens sequenced from Spain are originating from the entire National Influenza Surveillance System between weeks 44/2017 and 03/2018.

^c^ Sequence information is based on a sub-sample of influenza-positive samples received for surveillance at the National Influenza Center Denmark from week 40/2017 to 4/2018.

Among all ages, VE against influenza A(H3N2) ranged from −42% (95% CI: −116 to 7) in the DK and 7% (95% CI: −74 to 51) in the ES study. VE against hospitalisation for influenza A(H3N2) in patients aged 65 years and older was −1% (95% CI: −93 to 47) in EU-H ([Table 2](#t2){ref-type="table"}).

Influenza B
-----------

Of the 596 influenza B viruses sequenced, 94% (n = 559) were B/Yamagata (all belonging to clade 3 influenza B/Phuket/3073/2013) and 6% (n = 37) were influenza B/Victoria (25 belonging to clade 1A Δ(K162, N163) and 12 belonging to clade 1A) ([Table 3](#t3){ref-type="table"}).

Among all ages, VE against influenza B ranged between 36% (95% CI: 27 to 44) in the DK and 54% (95% CI: 24 to 72) in the UK study. Age group-specific VE was lowest at 15% (95% CI: −114 to 66) among those aged 65 years and older and highest at 83% (95%CI: 54 to 94) in the 0--14-year age group in the ES study. VE was 34% (95% CI: 8 to 52) against hospitalised influenza B in EU-H and 28% (95% CI: 14 to 39) against medically attended and hospitalised influenza B in the DK study among those aged 65 years and older ([Table 2](#t2){ref-type="table"}). VE against influenza B/Yamagata was 77% (95% CI: 14 to 94) in the ES study and 49% (95% CI: 19 to 67) in EU-PC ([Table 2](#t2){ref-type="table"}).

Sensitivity analyses
--------------------

For all of the above analyses, sensitivity analyses for small sample size gave similar results (absolute difference ranging between 1% and 6%).

Discussion
==========

Interim results from five established influenza VE studies across Europe indicate that 2017/18 VE against all influenza ranged between 25 and 52% among all ages and between 36 and 40% in the targeted groups. VE was moderate to good against influenza A(H1N1)pdm09 among all ages (55 to 68%), poor against influenza A(H3N2) with all point estimates below 8% for all ages, and moderate against influenza B, with point estimates between 39 and 52% for all ages.

The good VE against medically attended influenza A(H1N1)pdm09 is consistent with historical data \[[@r12]\]. However, during the last influenza A(H1N1)pdm09 season in Europe (2015/16), the EU-PC VE of 33% against influenza A(H1N1)pdm09 in all age groups was lower than what we report here \[[@r13]\]. In the 2015/16 season, the influenza vaccine strain A/California/7/2009 (H1N1)pdm09 differed from the circulating strains which mainly belonged to the genetic subgroup 6B.1 (represented by A/Michigan/45/2015 (H1N1)pdm09). This 6B.1 strain was included in the 2017/18 vaccine and was identified in all A(H1N1)pdm09 samples sequenced in the study sites. The change in vaccine strain may have led to a better VE against A(H1N1)pdm09. More precise end-of-season estimates and results at the hospital level will help investigate this hypothesis.

The influenza A(H3N2) component included in the 2017/18 northern hemisphere vaccine was the same as in the 2016/17 northern hemisphere vaccine \[[@r14]\]. As anticipated based on EU-H 2016/17 results \[[@r15]\] and 2017 interim results from Australia \[[@r16]\], and as already reported in other published early estimates for the northern hemisphere \[[@r17]\], the VE against influenza A(H3N2) was low in participating study sites. In our studies, 63% of sequenced influenza A(H3N2) viruses belonged to the A/HongKong/4801/2014 vaccine strain genetic group (3C.2a) and 35% to the A/Singapore/INFIMH-16--0019/2016 clade (3C.2a1), which is the selected strain in the 2018 southern hemisphere and 2018/19 northern hemisphere influenza vaccines \[[@r18]\]. Small sample size limited VE estimation by clade and subclade, which will be a priority for end-of-season analyses. Our results further support the need for more effective interventions in older people, in whom the burden of influenza A(H3N2) is most notable and the VE, including against severe outcome, is the lowest \[[@r19]\]. Based upon recent cost-effectiveness work undertaken by Public Health England, the UK Joint Committee on Vaccination and Immunisation has advised that use of adjuvanted trivalent inactivated vaccines (TIV) in those aged 65 years and older would be both more effective and cost-effective than the non-adjuvanted trivalent or quadrivalent vaccines currently in use \[[@r20]\].

The interim VE against medically attended influenza B was moderate in the studies included here (36% to 54% among all ages), similar to recently published estimates from northern hemisphere countries \[[@r17],[@r21],[@r22]\]. It was moderate to good against medically attended influenza B in children (58% in EU PC and 83% in ES) and poorer at 34% against hospitalised outcome among adults 65 years and older. The vast majority (94%) of sequenced influenza B samples were of the B/Yamagata lineage, which was not included in the 2017/18 northern hemisphere TIV. VE was 77% and 49% against influenza B/Yamagata in the ES and EU-PC studies, respectively, suggesting important cross-lineage protection.

The UK study was the only one to provide VE estimates for the quadrivalent vaccines. Vaccine effectiveness against any influenza among children was similar in the UK study (53%), where children receive LAIV4, and in the EU-PC study (59%), where most vaccinated children received TIV. However, it is difficult to compare these estimates against any influenza since the relative proportion of circulating (sub)types was different in the UK, where there was a higher proportion of circulating influenza A(H3N2) viruses, compared with most countries participating in the EU-PC study. In past seasons where circulating and vaccine lineages were different, contradictory results were observed \[[@r13],[@r23],[@r24]\]. Partial, but not full cross-protection between mismatched influenza B lineages has been suggested by two systematic reviews \[[@r25],[@r26]\]. More precise end-of-season estimates by lineage, age group and vaccine type would be of added value to discuss cross-lineage protection and the added protection conferred by quadrivalent vaccines. Such information is relevant at a time when QIV is available in most European countries \[[@r27]\] and preferentially recommended in some \[[@r28]\].

End-of-season analyses are needed to verify the conclusions from these interim season results. A larger sample size should allow more precise estimates, especially in stratified analyses. Recent publications suggest a potentially strong (boosting or lowering) effect of previous vaccination on VE estimates \[[@r29],[@r30]\] and end-of-season analyses should take this into account. Although TND is a well-recognised study design to measure VE, we cannot rule out bias from unmeasured confounding.

These early VE results from five studies were included in the Global Influenza VE (GIVE) report to help inform the World Health Organization vaccine strain selection committee meeting on 22 February 2018. For the 2018/19 northern hemisphere trivalent vaccine, this selection committee recommended to include the same influenza A(H1N1) component as in the 2017/18 northern hemisphere vaccine, an A/Singapore/INFIMH-16--0019/2016 (H3N2)-like virus and a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) \[[@r18]\].

In the context of an influenza season with co-circulation of influenza A(H3N2), influenza A(H1N1)pdm09 and influenza B viruses mismatched with the trivalent vaccine, results from these five EU studies indicate a moderate VE against all influenza. Vaccination continues to be the most effective preventive measure against influenza and uptake of the 2017/18 trivalent or quadrivalent influenza vaccines should still be promoted in countries with ongoing virus circulation. In particular in settings with evidence of influenza A(H3N2) virus circulation, prophylactic use of antiviral drugs, administered according to country-specific guidelines, could help prevent severe outcomes \[[@r31]\]. Based on our results and in the absence of major antigenic drift, we may expect a good protection of the 2018/19 northern hemisphere seasonal influenza vaccine against influenza A(H1N1) and B viruses. Monitoring the effectiveness of the 2018 southern influenza vaccine against influenza A(H3N2) viruses will be important to prepare for the next influenza season in the northern hemisphere.
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